AbbVie/Genmab lymphoma drug combo cut progression or death risk by 51% in trial
AbbVie Inc and Genmab A/S said their combination treatment for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) reduced the risk of disease progression or death by 51% compared with R-CHOP alone. The study tested epcoritamab in combination with R-CHOP in newly diagnosed patients with DLBCL.
Oct 5 (Reuters) — Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study. US-listed shares of Genmab were up about 11% in afternoon trading. 5%. com;)